GSK - GSK Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating, 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings or view top-rated stocks.

GSK's stock was trading at $44.10 at the beginning of the year. Since then, GSK stock has decreased by 33.2% and is now trading at $29.45.
View the best growth stocks for 2022 here.

GSK saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 13,970,000 shares, an increase of 10.0% from the August 31st total of 12,700,000 shares. Based on an average trading volume of 6,300,000 shares, the days-to-cover ratio is currently 2.2 days. Currently, 0.7% of the shares of the stock are short sold.
View GSK's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our GSK earnings forecast.

GSK plc (NYSE:GSK) posted its quarterly earnings data on Wednesday, July, 27th. The pharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.11. The pharmaceutical company earned $8.71 billion during the quarter, compared to analyst estimates of $9.35 billion. GSK had a net margin of 12.91% and a trailing twelve-month return on equity of 27.84%.

GSK announced a quarterly dividend on Wednesday, July 27th. Shareholders of record on Friday, August 19th will be given a dividend of $0.383 per share on Thursday, October 6th. This represents a $1.53 dividend on an annualized basis and a yield of 5.20%. The ex-dividend date is Thursday, August 18th. This is a positive change from the stock's previous quarterly dividend of $0.35.
Read our dividend analysis for GSK.

GSK (NYSE:GSK) pays an annual dividend of $1.53 per share and currently has a dividend yield of 5.20%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 50.66%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 44.22% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

GSK updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $49.73 billion-$50.67 billion, compared to the consensus revenue estimate of $38.72 billion.

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GSK stock can currently be purchased for approximately $29.45.

GSK (NYSE:GSK) has a market capitalization of $59.89 billion and generates $46.91 billion in revenue each year. The pharmaceutical company earns $6.03 billion in net income (profit) each year or $3.02 on an earnings per share basis.

The company employs 90,096 workers across the globe.

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.